

Amendments to the Claims

Listing of Claims:

Claim 1 (currently amended): A combination which comprises

(a) ~~a vasculostatic compound which is~~ PTK787 or a pharmaceutically acceptable salt thereof
and (b) ~~an alkylating agent~~ temozolomide.

in which the active ingredients (a) and (b) are present in each case in free form or in the form of a pharmaceutically acceptable salt for simultaneous, separate or sequential use.

Claims 2-6 (canceled)

Claim 7 (currently amended): A method of treating a patient ~~warm-blooded animal~~ having a tumor disease which comprises administering to the patient ~~animal~~ a combination according to claim 1 in a quantity which is jointly therapeutically effective against said tumor disease and in which the compounds can also be present in the form of their pharmaceutically acceptable salts, wherein the tumor disease is glioblastoma.

Claim 8 (currently amended): A method of inhibiting the formation of metastases in a patient ~~warm-blooded animal~~ having a tumor disease which comprises administering to the patient a pharmaceutically effective amount of a combination according to claim 1 in a quantity which is jointly therapeutically effective against said tumor disease and in which the compounds can also be present in the form of their pharmaceutically acceptable salts.

Claim 10 (canceled)

Claim 11 (previously presented): A method according to claim 8 wherein PTK787 is administered in a daily dose between 250 and 2000 mg.

Claim 12 (previously presented): A pharmaceutical composition comprising a quantity which is jointly therapeutically effective against a tumor disease of a pharmaceutical combination according to claim 1 and at least one pharmaceutically acceptable carrier.

Claim 13 (canceled)